Why is Merck stock rallying today?

Merck shares rose 2.1% in premarket trading after Q3 adjusted EPS of $2.49 beat the roughly $2.09 consensus and revenue of $18.1B exceeded expectations of about $17.3B. The company raised its full-year revenue floor to $66.8B and lifted adjusted EPS guidance to $2.77–$2.82 from $2.66–$2.76; Keytruda sales rose 6% to $8.6B and WINREVAIR sales surged 93% to $694M. The advance came against a softer broader premarket backdrop, while Keytruda’s 2028 patent cliff remains a longer-term concern.

Analysis

The beat matters most as evidence that near-term Keytruda erosion is not yet forcing a downgrade to the earnings base—not proof that the 2028 patent cliff is solved. QLEX may defend the franchise through convenience and administration-site economics, but its reported contribution could partly reflect patients switching formulations rather than incremental demand. Track total Keytruda growth alongside QLEX uptake and payer access to distinguish defense from genuine expansion.

WINREVAIR broadens the growth mix, but the commercial test is whether rapid adoption converts into durable treatment persistence and attractive economics as launch investment scales. In the next 1–3 months, revisions to forward estimates and adoption data matter more than analyst targets; the softer tape and pending macro releases create a risk that a strong print is initially faded. Over 6–18 months, pipeline readouts and evidence of repeatable growth outside Keytruda will determine whether investors assign a lower patent-cliff discount. The key reversal is decelerating Keytruda growth without enough offset from newer products, or guidance that fails to follow through. The contrarian point: investors may over-credit QLEX as a new growth engine when it could primarily extend the existing franchise; conversely, the scale and early adoption of newer products may be underappreciated if the market remains anchored to 2028.

Key Decisions for Investors

• Do not chase the premarket gap. Consider a staged MRK long after the open or on a pullback, with a 1–3 month horizon; the raised outlook and product mix support relative resilience, while macro data and post-earnings profit-taking create near-term entry risk.
• For a market-neutral expression, pair a modest MRK long with a short in a diversified large-pharma peer basket, sized to avoid treating a single earnings event as a sector-wide signal. Reassess after the next update on Keytruda growth and new-product adoption.
• Monitor whether QLEX growth is accompanied by stable or improving total Keytruda demand, and whether WINREVAIR adoption persists. If newer-product uptake stalls or total Keytruda growth turns negative before meaningful offsets emerge, reduce or exit the long thesis.
• Treat the patent-cliff discount as unresolved: verify launch timing, competitive entry assumptions, and pipeline readouts before underwriting durable post-2028 growth. A guidance reduction or material deterioration in forward estimates would falsify the near-term positive read.